

Oxurion confirms continuation of discussions regarding its proposed acquisition of a French CRO

Leuven, BELGIUM – 27 februari 2026 – 06:00 PM CET – [Oxurion NV](#) (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces the extension of the negotiations relating to the proposed acquisition of a majority stake in a French CRO, as previously announced on 13 October 2025.

This extension aims to continue the due diligence process. The ongoing analyses are intended to confirm the robustness of the target’s business plan.

Oxurion is taking an additional three months to finalize this work and will inform the market of any further developments.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a company specializing in acquiring majority stakes in promising European pharmaceutical subcontractors. Oxurion’s ambition is to build an integrated group of subcontractors serving healthcare players. The Group’s headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

Additional Disclaimer

The planned investment in digital assets (such as Bitcoin and Ethereum) exposes the company to specific risks related to volatility, regulatory uncertainty, and cybersecurity. These factors may significantly affect the expected performance of the investments.

Please contact for additional information:

<p>Oxurion NV Pascal Ghoson Chief Executive Officer pascal.ghoson@oxurion.com</p>
--